ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / NAGE
GLAS (18) MDWD (51) ACB (54) USNA (50) ⌘ Pro Terminal →

Niagen Bioscience Inc. (NAGE) — RQD Stock Rating Cockpit

$2.33 -6.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.30

Niagen Bioscience Inc. (NAGE) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $197.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NAGE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NAGE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Niagen Bioscience Inc. (NASDAQ: NAGE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $2.33 (-6.80% 1D, market cap $197.8M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 18/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NAGE compare to GLAS and MDWD in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), NAGE carries a Roarable D+ (57/100 RQD), trailing P/E of 11.4x, gross margin of 64.3%, and ROIC of 16.8%. By comparison, GLAS (Glass House Brands Inc. Subordinate Voting Shares) holds a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M) and MDWD (MediWound Ltd.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $178.9M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NAGE?
▼

Per NAGE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001386570), Niagen Bioscience Inc. generated $129.4M in revenue (+29.9% YoY), $17.4M in net income, and $13.5M in free cash flow against $106.4M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.30 (-1.41%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 10.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510057
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Cash (13)Whales (3)SEC (14)Macro (9)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE-0.4% Base Target
$8 Bull$2 Base$2 Bear
📬 FREE NAGE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAGE)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY NAGE SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (32% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)

Altman Z-Score 4.40 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
65
Grade C+$2.63-4.9% Next Q
Q2 (-2Q)
62
Grade C+$2.50-2.4% Next Q
Q3 (-1Q)
60
Grade C$2.44-4.5% Next Q
Current
57
Grade D+$2.33-0.2% Hist 90D α
Trajectory: C+ (65) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NAGE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, NAGE faces multiple-compression risk if 11.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 61.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.84) or 200D SMA ($3.90) invalidates the momentum regime and cuts Target Base ($2.32) toward Bear Floor ($1.81).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAGE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NAGE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 57%NO 43%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
43.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
4.40>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $2$2.33H: $8
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (64% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D+RQD 21 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on NAGE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (65)

16.8% ROIC with 64.3% gross margin and 6.83% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 4.40 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (50)

21/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like NAGE
  • ✓Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAGE)

  • ✓Walkthrough of NAGE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NAGE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.74%🛡️ HOLDING TREND SUPPORT
2026-11-02O $2.54H $2.54L $2.33C $2.33VOL 348.4K
RES: $2.69SUP: $2.13SMA50: $2.84SMA200: $3.90
$7.26$5.92$4.58$3.24$1.90RES $2.69SUP $2.13$2.332026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NAGE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NAGE Butterfly Map → + Track NAGE →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
1.5%/yr Implied 5Y Growth

vs. +29.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NAGE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NAGE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NAGE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAGE)

Health Care Rank #212 of 1016 ⚔️ GLAS vs NAGE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NAGE vs. GLAS, MDWD, ACB, USNA)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Niagen Bioscience Inc. (NAGE) ranks #212 by composite RQD confidence (57/100, grade D+) and #580 by equity capitalization ($197.8M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NAGE ACTIVE
Niagen Bioscience Inc.
D+ 57/100 11.4x 64.3% 16.8% -6.80% $197.8M Benchmark Subject
GLAS
Glass House Brands Inc. Subordinate Voting Shares
E 18/100 — 42.3% -9.2% -4.39% $200.6M /glas-vs-nage →
MDWD
MediWound Ltd.
D 51/100 — — — -4.04% $178.9M /mdwd-vs-nage →
ACB
Aurora Cannabis Inc.
D+ 54/100 — — — -0.49% $252.8M /acb-vs-nage →
USNA
USANA Health Sciences Inc.
D 50/100 24.6x 78.3% 7.9% -0.21% $265.0M /usna-vs-nage →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001386570

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niagen Bioscience Inc. (NAGE) reported GAAP revenue of $129.4M (+29.9% vs. FY2024 revenue of $99.6M , and +54.9% cumulative change since FY2023) , GAAP net income of $17.4M, operating cash flow of $13.5M, and free cash flow of $13.5M (+11.5% YoY). On the balance sheet, NAGE closed FY2025 with $106.4M in total assets against $0 in total debt (Altman Z-Score: 4.40, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $129.4M $17.4M $13.5M $13.5M $106.4M —
FY2024 (FY) 2024-12-31 $99.6M $8.6M $12.1M $12.1M $68.3M —
FY2023 (FY) 2023-12-31 $83.6M -$4.9M $7.1M $7.1M — —

3. NAGE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NAGE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Niagen Bioscience Inc. (NASDAQ: NAGE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $2.33 (-6.80% 1D, market cap $197.8M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 18/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does NAGE compare to GLAS and MDWD in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), NAGE carries a Roarable D+ (57/100 RQD), trailing P/E of 11.4x, gross margin of 64.3%, and ROIC of 16.8%. By comparison, GLAS (Glass House Brands Inc. Subordinate Voting Shares) holds a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M) and MDWD (MediWound Ltd.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $178.9M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NAGE?

Per NAGE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001386570), Niagen Bioscience Inc. generated $129.4M in revenue (+29.9% YoY), $17.4M in net income, and $13.5M in free cash flow against $106.4M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NAGE trading relative to its 50-day, 200-day, and 52-week technical levels?

NAGE last traded at $2.33 (-6.80% on volume of 526,369 shares), positioning the stock -17.96% below its 50-day simple moving average ($2.84) and -40.26% below its 200-day simple moving average ($3.90). Across its 52-week range of $2.32 to $7.95, NAGE sits at the 0.2% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($2.16 to $2.50).

NAGE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell NAGE stock right now?

Niagen Bioscience Inc. (NAGE) currently earns a Roarable Rating of D+ (Sell — SELL) with 57/100 RQD Confidence. Stretched risk/reward at 11x P/E (17% return on capital) under elevated 10-year interest-rate pressure.

What is NAGE's 12-month price target and RQD AI Jury consensus?

NAGE's 12-month base price target is $2.32 (range $1.81 to $8.35), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: NAGE RQD Cockpit NAGE 12M Forecast NAGE Earnings & Move NAGE Dividends & DRIP NAGE Insiders & 13F NAGE Whale Options NAGE Profit Sankey NAGE News & Why
ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NAGE — Niagen Bioscience Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:41:18Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NAGE scores 57 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 13/20 (ROIC 16.8%; FCF yield 6.83%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 18/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 14/20 (Altman Z 4.4; Piotroski F 7/9; Debt/Equity 0.5).

For a prospective investor, the profile is uneven. The strongest pillar is insider conviction (18/20), which per the rating reflects cluster flow in SEC Form 4 and Congressional PTR data. The weakest pillar is institutional flow (3/20), indicating limited 13F accumulation and options positioning support. The cash engine and balance sheet pillars are moderate, while macro regime fit is below midpoint given the 1.0 beta and the liquidity-sensitivity signal in the Butterfly graph. Upside drivers cited in the data include the insider cluster flow and the cash-generation metrics; the valuation tradeoff is that the stock trades at a trailing P/E of 11.4 and forward P/E of 9.6 against a 52-week range of $2.32 - $7.95 and a current price of $2.5, which the rating does not translate into a fair-value view. The rating verdict reflects an overall "Trim" stance on weak aggregate fundamentals rather than a directional price forecast.

Snapshot

MetricValue
Price$2.5 (-1.57%)
Market Cap$197.8M
P/E (TTM)11.4
Forward P/E9.6
EV/EBITDA12.2
EPS (TTM)0.22
Dividend Yield0%
Beta1.0
52-Wk Range$2.32 - $7.95
ROIC %16.8%

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the headlines are: an Yahoo Finance preview stating NAGE's Q3 earnings are expected to decline; a TradingView estimates item; a Canaccord reiteration of the rating on the healthy-aging strategy; a GuruFocus item on a clinician-directed at-home injectable launch; a Business Wire notice that Q3 2026 results will be reported on Wednesday, November 4, 2026; and a MarketBeat item noting a $9.00 price target from Canaccord Genuity Group. All items carry a YELLOW light and MARKET WIRE impact label.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE with no butterfly links. The proprietary signal is a LIQUIDITY_TAILWIND, terminal label "MACRO TAILWIND SCORE (25/100)," severity 88, direction BEARISH. It reports the True Net Liquidity Index at $5,745.73B (-0.64% 4-week RoC; High-Yield OAS +2 bps) and a rolling 5-year Net Liquidity beta of 2.64x for NAGE (r = +0.24). Risk watch items are the earnings expectation decline and the bearish liquidity signal.

Open Questions

  • What are the specific insider transactions (Form 4 and Congressional PTR) underlying the 18/20 insider conviction score?
  • What is the consensus analyst rating and price-target distribution beyond the single referenced Canaccord Genuity target?
  • What are FY 2025 cash, debt, and EPS figures, which are listed as N/A in the financial table?
  • What customer concentration, product, and revenue-mix details drive the FY 2024 to FY 2025 revenue step-up?
  • What supply-chain dependencies exist, given the Butterfly graph lists none?

NAGE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Niagen Bioscience Inc. (NAGE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NAGE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NAGE Bull vs. Bear Conversation Board — What's Your Call at $2.33?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NAGE 🐻 50% BEARISH CONVICTION
1. Pick Your Side on NAGE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $2.70 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NAGE (D+ • RQD 57/100) a Buy at $2.50?

Welcome to the NAGE (Niagen Bioscience Inc.) Roar Pit. Current RQD Composite is 57/100 (Roarable Sell — Weak Fundamentals / Trim) in Medicinal Chemicals and Botanical Products. Bulls point to capital efficiency (16.8% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.98 (-20.8%)
Spot @ $2.50

Pump the brakes on NAGE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NAGE, but look at what you are paying: 11.4x trailing P/E with 64.3% gross margins. Unless Niagen Bioscience Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.10 (+24.0%)
Spot @ $2.50

NAGE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NAGE, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $2.50 (52-wk range $2.32 - $7.95), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%